These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35768832)

  • 21. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma.
    Hu ZG; Zheng CW; Su HZ; Zeng YL; Lin CJ; Guo ZY; Zhong FD; Yuan GD; He SQ
    J Cell Biochem; 2019 Jun; 120(6):9964-9978. PubMed ID: 30582202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTTG1 regulated by miR-146a-3p promotes bladder cancer migration, invasion, metastasis and growth.
    Xiang W; Wu X; Huang C; Wang M; Zhao X; Luo G; Li Y; Jiang G; Xiao X; Zeng F
    Oncotarget; 2017 Jan; 8(1):664-678. PubMed ID: 27893422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis.
    Fujii T; Nomoto S; Koshikawa K; Yatabe Y; Teshigawara O; Mori T; Inoue S; Takeda S; Nakao A
    Hepatology; 2006 Jun; 43(6):1267-75. PubMed ID: 16628605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and Prognostic Values of the Roof Plate-Specific Spondin Family in Bladder Cancer.
    Gao L; Meng J; Zhang M; Fan S; Gao S; Wang X; Liang C
    DNA Cell Biol; 2020 Jun; 39(6):1072-1089. PubMed ID: 32352838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment.
    Ma J; Hu J; Zhao L; Wu Z; Li R; Deng W
    BMC Urol; 2024 Jan; 24(1):6. PubMed ID: 38172792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-associated fibroblasts and the related Runt-related transcription factor 2 (RUNX2) promote bladder cancer progression.
    Liu B; Pan S; Liu J; Kong C
    Gene; 2021 Apr; 775():145451. PubMed ID: 33482279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SIRT1 suppresses pituitary tumor progression by downregulating PTTG1 expression.
    Huang J; Zhang F; Hu G; Pan Y; Sun W; Jiang L; Wang P; Qiu J; Ding X
    Oncol Rep; 2022 Aug; 48(2):. PubMed ID: 35730625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
    Li H; Zhang Y; Zheng S
    Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen-regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression.
    Meng C; Zou Y; Hong W; Bao C; Jia X
    Mol Med; 2020 Apr; 26(1):33. PubMed ID: 32272902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
    Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA.
    Ding Y; Liu N; Chen M; Xu Y; Fang S; Xiang W; Hua X; Chen G; Zhong Y; Yu H
    World J Surg Oncol; 2021 Apr; 19(1):133. PubMed ID: 33888142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.
    Huang Z; Yan Y; Wang T; Wang Z; Cai J; Cao X; Yang C; Zhang F; Wu G; Shen B
    J Transl Med; 2022 Jul; 20(1):315. PubMed ID: 35836227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer.
    Sun Y; Sedgwick AJ; Khan MA; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():724107. PubMed ID: 34858395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioinformatics Analysis to Screen the Key Prognostic Genes in Tumor Microenvironment of Bladder Cancer.
    Zhang Z; Chen D; Li Z; Liu Z; Yan L; Xu Z
    Biomed Res Int; 2020; 2020():6034670. PubMed ID: 32149116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the pituitary tumor transforming gene 1 in the progression of hepatocellular carcinoma.
    Liang M; Chen X; Liu W; Li S; Li C; Jiang L; Lv S
    Cancer Biol Ther; 2011 Feb; 11(3):337-45. PubMed ID: 21099350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.